Resolve Therapeutics Publishes Results of RSLV-132 Phase 2 Long COVID Study
Resolve Therapeutics, a mid-stage clinical development company pioneering transformative therapies for autoimmune and post-viral illnesses, today announced the publication of its phase 2 long COVID results in Clinical Infectious Diseases.